By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agios Pharmaceuticals 

38 Sidney Street
2nd Floor
Cambridge  Massachusetts  02139-4169  U.S.A.
Phone: 617-649-8600 Fax: n/a


SEARCH JOBS

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

YEAR FOUNDED:

August 7, 2007

LEADERSHIP:

Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su

CEO: David Schenkein

CMO (Medical): Chris Bowden

CSO (Scientific): Scott Biller

JOBS:

Please click here for Agios job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Public

Web Site: Agios
Employees:
Symbol: AGIO
 









Company News
Former BIND Therapeutics (BIND) CEO Joins Agios (AGIO) as New CFO 8/16/2016 6:53:50 AM
Agios (AGIO) To Present At Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016 8/5/2016 10:09:00 AM
Agios (AGIO) Reports Second Quarter 2016 Financial Results 8/4/2016 11:26:20 AM
Agios (AGIO)' Anemia Drug Data Hits Mark in Mid-Stage Study 6/13/2016 7:28:20 AM
Agios (AGIO) Reports Initial Data From Phase I Study Of AG-519 In Healthy Volunteers 6/9/2016 1:35:43 PM
Agios (AGIO), Celgene (CELG) Hammer Out $1 Billion+ Metabolic Immuno-Oncology Deal 5/18/2016 5:53:11 AM
10 Massachusetts Biotechs Devoting the Most Cash to R&D 5/5/2016 6:29:13 AM
Agios (AGIO) Appoints Steve Hoerter As Chief Commercial Officer 2/8/2016 10:28:28 AM
Agios (AGIO) To Present At The 34th Annual J.P. Morgan Healthcare Conference On Monday, January 11 1/4/2016 7:15:21 AM
Agios (AGIO) Announces Data From Ongoing Phase I Trial Of AG-120 Showing Durable Responses In Patients With Advanced Hematologic Malignancies 12/7/2015 7:38:20 AM
12345678910...
//-->